| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Endocrinology, Vol 8, 296-304, Copyright © 1994 by Endocrine Society
ARTICLES |
N Fujimoto and BS Katzenellenbogen
Department of Physiology and Biophysics, University of Illinois, Urbana 61801.
We find that stimulation of the protein kinase A (PKA) signaling pathway in MCF-7 human breast cancer cells changes the agonist/antagonist activity of tamoxifen and related antiestrogens; it activates or enhances their estrogen agonist activity and reduces their ability to antagonize the effects of estradiol (E2). In MCF-7 human breast cancer cells which contain high levels of endogenous estrogen receptor (ER), the antiestrogen trans-hydroxy-tamoxifen (TOT) fails to stimulate transcription of the estrogen-responsive promoter-reporter constructs estrogen response element (ERE)-TATA-chloramphenicol acetyl transferase (CAT), (ERE)2-TATA-CAT, and pS2-CAT. However, when cells are treated with isobutyl methylxanthine plus cholera toxin (which increases intracellular cAMP approximately 10-fold), or with 8-bromo- cAMP, or are transfected with expression vectors for the PKA catalytic subunits, the transcriptional activity of the antiestrogen-ER complex is now increased, to levels 20-75% that of E2, and TOT also becomes much less effective in antagonizing the stimulation of transcription by E2. Although this alteration in the agonist and antagonist activity of TOT is observed with three promoter-reporter constructs, containing a simple TATA promoter or a more complex, pS2 promoter, elevation of cAMP did not enhance the transcription by either TOT or E2 of the reporter plasmid ERE-thymidine kinase-CAT. Thus, this phenomenon is promoter specific. The maximal stimulatory effects of isobutylmethylxanthine plus cholera toxin and PKA catalytic subunits on TOT and E2 transcriptional enhancement were not additive, consistent with the hypothesis that they are both acting via stimulation of the same signal transduction pathway.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
 |
|
 |
|
  J. K. Nagpal, S. Nair, D. Chakravarty, R. Rajhans, S. Pothana, D. W. Brann, R. R. Tekmal, and R. K. Vadlamudi Growth Factor Regulation of Estrogen Receptor Coregulator PELP1 Functions via Protein Kinase A Pathway Mol. Cancer Res., May 1, 2008; 6(5): 851 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Vasudevan and D. W. Pfaff Membrane-Initiated Actions of Estrogens in Neuroendocrinology: Emerging Principles Endocr. Rev., February 1, 2007; 28(1): 1 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Al-Dhaheri and B. G. Rowan Protein Kinase A Exhibits Selective Modulation of Estradiol-Dependent Transcription in Breast Cancer Cells that Is Associated with Decreased Ligand Binding, Altered Estrogen Receptor {alpha} Promoter Interaction, and Changes in Receptor Phosphorylation Mol. Endocrinol., February 1, 2007; 21(2): 439 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Coleman, M. Dutertre, A. El-Gharbawy, B. G. Rowan, N. L. Weigel, and C. L. Smith Mechanistic Differences in the Activation of Estrogen Receptor-alpha (ERalpha )- and ERbeta -dependent Gene Expression by cAMP Signaling Pathway(s) J. Biol. Chem., April 4, 2003; 278(15): 12834 - 12845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawashima, K. Yamakawa, W. Takahashi, S. Takizawa, P. Yin, N. Sugiyama, S. Kanba, and J. Arita The Estrogen-Occupied Estrogen Receptor Functions as a Negative Regulator to Inhibit Cell Proliferation Induced by Insulin/IGF-1: A Cell Context-Specific Antimitogenic Action of Estradiol on Rat Lactotrophs in Culture Endocrinology, July 1, 2002; 143(7): 2750 - 2758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Klinge, S. C. Jernigan, and K. E. Risinger The Agonist Activity of Tamoxifen Is Inhibited by the Short Heterodimer Partner Orphan Nuclear Receptor in Human Endometrial Cancer Cells Endocrinology, March 1, 2002; 143(3): 853 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lazennec, L. Canaple, D. Saugy, and W. Wahli Activation of Peroxisome Proliferator-Activated Receptors (PPARs) by Their Ligands and Protein Kinase A Activators Mol. Endocrinol., December 1, 2000; 14(12): 1962 - 1975. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Dutertre and C. L. Smith Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 431 - 437. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Kurokawa, A. E. G. Lenferink, J. F. Simpson, P. I. Pisacane, M. X. Sliwkowski, J. T. Forbes, and C. L. Arteaga Inhibition of HER2/neu (erbB-2) and Mitogen-activated Protein Kinases Enhances Tamoxifen Action against HER2-overexpressing, Tamoxifen-resistant Breast Cancer Cells Cancer Res., October 1, 2000; 60(20): 5887 - 5894. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. S. Katzenellenbogen Mechanisms of Action and Cross-Talk Between Estrogen Receptor and Progesterone Receptor Pathways Reproductive Sciences, January 1, 2000; 7(1_suppl): S33 - S37. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. Hilsenbeck, W. E. Friedrichs, R. Schiff, P. O'Connell, R. K. Hansen, C. K. Osborne, and S. A. W. Fuqua Statistical Analysis of Array Expression Data as Applied to the Problem of Tamoxifen Resistance J Natl Cancer Inst, March 3, 1999; 91(5): 453 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Watters and D. M. Dorsa Transcriptional Effects of Estrogen on Neuronal Neurotensin Gene Expression Involve cAMP/Protein Kinase A-Dependent Signaling Mechanisms J. Neurosci., September 1, 1998; 18(17): 6672 - 6680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, M. Jeyakumar, S. Petukhov, and M. K. Bagchi A Nuclear Receptor Corepressor Modulates Transcriptional Activity of Antagonist-Occupied Steroid Hormone Receptor Mol. Endocrinol., April 1, 1998; 12(4): 513 - 524. [Abstract] [Full Text]
|
|
|
|
|
|
J. D. Norris, D. Fan, M. R. Stallcup, and D. P. McDonnell Enhancement of Estrogen Receptor Transcriptional Activity by the Coactivator GRIP-1 Highlights the Role of Activation Function 2 in Determining Estrogen Receptor Pharmacology J. Biol. Chem., March 20, 1998; 273(12): 6679 - 6688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Lavinsky, K. Jepsen, T. Heinzel, J. Torchia, T.-M. Mullen, R. Schiff, A. L. Del-Rio, M. Ricote, S. Ngo, J. Gemsch, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes PNAS, March 17, 1998; 95(6): 2920 - 2925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Wagner, J. D. Norris, T. A. Knotts, N. L. Weigel, and D. P. McDonnell The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor Mol. Cell. Biol., March 1, 1998; 18(3): 1369 - 1378. [Abstract] [Full Text]
|
|
|
|
|
|
S. Kahmann, L. Vaßen, and L. Klein-Hitpass Synergistic Enhancement of PRB-Mediated RU486 and R5020 Agonist Activities through Cyclic Adenosine 3',5'-Monophosphate Represents a Delayed Primary Response Mol. Endocrinol., February 1, 1998; 12(2): 278 - 289. [Abstract] [Full Text]
|
|
|
|
|
|
C. L. Smith, Z. Nawaz, and B. W. O’Malley Coactivator and Corepressor Regulation of the Agonist/Antagonist Activity of the Mixed Antiestrogen, 4-Hydroxytamoxifen Mol. Endocrinol., June 1, 1997; 11(6): 657 - 666. [Abstract] [Full Text]
|
|
|
|
|
|
T. A. Jackson, J. K. Richer, D. L. Bain, G. S. Takimoto, L. Tung, and K. B. Horwitz The Partial Agonist Activity of Antagonist-Occupied Steroid Receptors Is Controlled by a Novel Hinge Domain-Binding Coactivator L7/SPA and the Corepressors N-CoR or SMRT Mol. Endocrinol., June 1, 1997; 11(6): 693 - 705. [Abstract] [Full Text]
|
|
|
|
|
|
M. M. Montano, W. L. Kraus, and B. S. Katzenellenbogen Identification of a Novel Transferable cis Element in the Promoter of an Estrogen-Responsive Gene that Modulates Sensitivity to Hormone and Antihormone Mol. Endocrinol., March 1, 1997; 11(3): 330 - 341. [Abstract] [Full Text]
|
|
|
|
|
|
K. Ekena, K. E. Weis, J. A. Katzenellenbogen, and B. S. Katzenellenbogen Different Residues of the Human Estrogen Receptor Are Involved in the Recognition of Structurally Diverse Estrogens and Antiestrogens J. Biol. Chem., February 21, 1997; 272(8): 5069 - 5075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Massaad, M. Lombes, M. Aggerbeck, M.-E. Rafestin-Oblin, and R. Barouki Cell-Specific, Promoter-Dependent Mineralocorticoid Agonist Activity of Spironolactone Mol. Pharmacol., February 1, 1997; 51(2): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. Nazareth and N. L. Weigel Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway J. Biol. Chem., August 16, 1996; 271(33): 19900 - 19907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ekena, K. E. Weis, J. A. Katzenellenbogen, and B. S. Katzenellenbogen Identification of Amino Acids in the Hormone Binding Domain of the Human Estrogen Receptor Important in Estrogen Binding J. Biol. Chem., August 16, 1996; 271(33): 20053 - 20059. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
